Nonopioid Alternatives Pamphlet

Posted in Latest News on July 2, 2019.

House Bill 451, Nonopioid Alternatives, was approved by Governor DeSantis and is effective July 1, 2019. The bill requires that before providing anesthesia or prescribing, ordering, dispensing, or administering an opioid listed as a Schedule II controlled substance to treat pain, the patient must be informed about available nonopioid alternatives. A healthcare practitioner will discuss the advantages and disadvantages of using nonopioid alternatives. Under the new law, the department is required to develop an educational pamphlet about using nonopioid alternatives and post the pamphlet on the department’s website. Healthcare practitioners must provide the patient with this educational pamphlet. Those healthcare practitioners providing emergency services and care are exempt from these requirements.

Click here for pamphlets and additional information.



More Latest News

Important notice regarding Inveltys
August 7, 2019

The board approved Inveltys (loteprednol etabonate ophthalmic suspension) 1% for addition to Rule 64B13-18.002. Effective August 5, 2019, Licensees are now permitted to prescribe Inveltys. Continue reading


Brand Names not allowed on formulary.
July 23, 2019

The Board of Optometry met on July 18, 2019 in Orlando regarding adding Rocklatan to the formulary. Click here for more information on the formulary. Continue reading